Search - tctmd.com

Displaying 601 - 620 of 766

Sort: Relevancy | Date

News Industry News

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 15, 2012

News Conference News

Study Examines Influence of Baseline Factors on Outcomes After CABG, PCI

L.A. McKeown

May 11, 2012

News Daily News

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

May 10, 2012

News Industry News

Clinical Data for OrbusNeich’s Combo Dual Therapy Stent™ Set for Presentation at EuroPCR 2012

May 08, 2012

News Daily News

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

L.A. McKeown

April 25, 2012

News Daily News

TRIGGER-PCI Published: Halted Trial Questions Platelet Testing in Stable Patients

April 19, 2012

News Daily News

First Implanted Biodegradable Stent Shows Positive Safety at 10 Years

Jason Kahn

April 17, 2012

News Industry News

Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan

April 09, 2012

News Daily News

Baseline Anemia Raises Risk for Stent Thrombosis After DES

L.A. McKeown

April 04, 2012

News Industry News

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

March 27, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

News Industry News

Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Daily News

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Jason Kahn

March 22, 2012

News Daily News

Pulmonary Vein Stenting in Children Temporarily Improves Stenosis But Not Prognosis

March 21, 2012

News Industry News

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

March 20, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

ASCERT: Long-term Survival Appears to Favor CABG Over PCI for Multivessel Disease

L.A. McKeown

March 07, 2012

Advertisement

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

Study Examines Influence of Baseline Factors on Outcomes After CABG, PCI

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

Clinical Data for OrbusNeich’s Combo Dual Therapy Stent™ Set for Presentation at EuroPCR 2012

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

TRIGGER-PCI Published: Halted Trial Questions Platelet Testing in Stable Patients

First Implanted Biodegradable Stent Shows Positive Safety at 10 Years

Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan

Baseline Anemia Raises Risk for Stent Thrombosis After DES

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

Boston Scientific Supports New Clinical Trial to Evaluate Platinum Chromium Coronary Stents in Treating Heart Attack Patients

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Pulmonary Vein Stenting in Children Temporarily Improves Stenosis But Not Prognosis

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

Celecoxib Enhances DES Efficacy, But at Clinical Cost

ASCERT: Long-term Survival Appears to Favor CABG Over PCI for Multivessel Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content